CRISPR Therapeutics (CRSP) PT Raised to $166 at Chardan Capital Markets
Tweet Send to a Friend
Chardan Capital Markets analyst Geulah Livshits raised the price target on CRISPR Therapeutics (NASDAQ: CRSP) to $166.00 while maintaining a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
